# What a registered acute-wound study plans to measure

- Article ID: research-125
- Product: GHK-Cu (ghk-cu-564)
- Canonical page: https://heritagebiolabs.com/research-library/articles/125-what-a-registered-acute-wound-study-plans-to-measure
- Product collection: https://heritagebiolabs.com/research-library/products/ghk-cu
- Product page: https://heritagebiolabs.com/product/ghk-cu-564
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids held together by peptide bonds. Some interact with cells involved in tissue repair. GHK-Cu is a three-amino-acid peptide bound to copper. A phase 2 study registered in February 2026 proposes to evaluate it for closure of acute skin wounds in healthy adults. Its public record describes a question and a planned comparison. [1]

The investigators selected a primary outcome called time to complete re-epithelialization. The term refers to the return of a continuous outer layer of skin across the wound. This is a structural milestone that can be assessed from clinical examination and images. Scar appearance later on is a separate outcome, because a wound can close before the new tissue has finished remodeling. The trial record also describes an assessment of safety. [1]

The comparison uses a control product and examines outcomes within each participant. This design can help account for differences in healing among people. The registry also specifies blinded assessment, which reduces the chance that an evaluator's knowledge of the assignment influences the judgment. The resulting estimates will depend on whether the planned measurements can be collected and whether the observed differences are large enough to distinguish from variation. [1]

The record listed the study as recruiting and had no results posted when checked on November 8, 2026. Its scope is acute wounds in healthy adults. Chronic wounds, wounds in people with diabetes and recovery after different procedures would each require evidence relevant to those circumstances. A registry describes what a study is designed to learn. The outcome itself comes from completed data and analysis. [1]

## Sources

1. Hudson Biotech. A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults. ClinicalTrials.gov (publication 2026-02-27). <https://clinicaltrials.gov/study/NCT07437586>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 025 - Fragment 176-191 and GHK-Cu.docx; article 125; content SHA-256 cb35ab0a145ad17731abea2bdf1472f46949fd9e2ddb529d5c4ff3a9e3e1bbd2.
